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1. Introduction 
Hodgkin’s lymphoma (HL) is a highly curable disease and the reported results in last years 
relative to patient’s survival were continuously improved. Cure rates > 90% for early HL 
and > 70% for those with advanced HL are expected. Nevertheless, there are high-risk 
patients (about 35%) refractory to initial treatment or relapse after achieving complete 
remission. The current approaches to identify these patients employ pathologic, clinical and 
classical biologic prognostic factors. The relative scarcity of markers that could reliably 
predict long-term survival generates excessive treatments with both radio- and 
chemotherapy for many patients. In this condition, the identification of innovative biologic 
markers that could help to design appropriately tailored treatment strategies for classic HL 
(cHL) patients at high risk of treatment failure and patients with low-risk disease remains a 
crucial challenge.  
The presence of a characteristic inflammatory microenvironment in response to tumoral 
cells not only distinguishes HL from other lymphomas, but even more, this is the main 
characteristic that makes HL a separate entity itself allowing its diagnosis. However, the 
functional role of the microenvironment in the pathophysiology of HL remains a matter of 
debate. The ability of the immune system to act as a double-edge weapon, protective or 
stimulating, indicates that tumoral clearance requires the effective coordination of the 
different elements of the immune system in an appropriate balance in quantity and quality. 
Therefore, current cancer research in HL aims to develop methods to increase the 
effectiveness of host antitumoral immune response, or at least prevent that various 
cytokines and growth factors from different subpopulation of infiltrating reactive immune 







Biological therapy (also called immunotherapy, biotherapy or biological response modifier 
therapy) is one of the most promising strategies. These therapies use the body’s immune 
system, either directly or indirectly, to fight HL or to help lessen the side effects of some 
cancer treatments for HL. Current biological therapy treatments for HL may be used either 
alone or in conjunction with other modalities such surgery, radiation and chemotherapy. 
This chapter summarizes the data on clinical, histological, pathological and biological 
factors in HL, with special emphasis on the improvement of prognosis and their impact on 
therapeutical strategies. The recent advances in our understanding of HL biology and 
immunology seem indicate that infiltrated immune cells in the tumoral microenvironment 
may play different, even opposite, functions according to the signals it senses. Strategies 
aimed at interfering with the crosstalk between H/RS cells and their cellular partners have 
been taken into account in the development of new immunotherapy’s that target different 
cell components of HL microenvironment. The current standard approaches with the use of 
combined modality therapy and systemic chemotherapy as well as the promising role of 
future response-adapted strategies is reviewed. 
2. Histopathological diagnostic parameters 
As classified by the World Health Organization (WHO), HL exists in 5 types (Swerdlow et 
al., 2008b). Four of these—nodular sclerosis (NSHL), mixed cellularity (MCHL), lymphocyte 
depleted (LDHL), and lymphocyte rich (LRHL)—are referred to as cHL. The fifth type, 
nodular lymphocyte predominant Hodgkin disease (NLPHL), accounts for 4–5% of all HL 
cases and is a distinct entity with unique clinical features and a different treatment 
paradigm. Regarding cHL, NSHL represents the most common histological type in 
European countries, accounting for 40–70% of cases whereas MCHL account for about 30%.  
Histologically, cHL is characterized by a minority of neoplastic cells (1-2%) named H/RS 
cells embedded in a rich background composed of a variety of reactive, mixed inflammatory 
cells consisting of lymphocytes, plasma cells, neutrophils, eosinophils, and histiocytes 
(Figure 1A). Thus, the presence of an appropriate cellular background—along with the 
results of immunophenotyping—is basic for the diagnosis. Evidence has accumulated that 
H/RS cells harbor clonally rearranged and somatically mutated immunoglobulin genes, 
indicating their derivation, in most cases, from germinal center (GC) B-cells (Kuppers, 2002; 
Kuppers et al., 2003; Staudt, 2000; Thomas et al., 2004). Some HL cases have been identified 
in which the H/RS is of T-cell origin but these are rare, accounting for 1-2% of cHL. Under 
normal conditions, GC B-cells, that lack a functional high affinity antibody, undergo 
apoptosis in the germinal center. H/RS cells show a characteristically defective B-cell 
differentiation program, lose the capacity to express immunoglobulin and, therefore, should 
die. However, H/RS cells escape apoptosis and instead proliferate, giving rise to the tumor 
and the immune response that characterizes (Kuppers, 2002; Kuppers et al., 2003; Staudt, 
2000; Thomas et al., 2004). Gray zones between cHL and some types of diffuse B-cell 
lymphoma, especially primary mediastinal large B-cell lymphoma have been appreciated 
during these last 20 years (Campo et al., 2011). Both share a close biologic relationship and 
similar profiling at the epigenetic level (Eberle et al., 2011). 
Concerning the phenotypic findings, expression of the CD30 molecule by H/RS cells is seen 
in more than 98% of cHLs although the intensity of the immunostaining can vary from one 
case to another, and even within the same case. CD30 molecule appears also to be a possible 
target for specific antibodies conjugated with toxins and administered to patients with cHL  
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Fig. 1. Reed-Sternberg cell (A: black arrow) seen in a cellular background rich in 
lymphocytes of a classical Hodgkin lymphoma.  Popcorn cell (B: black arrow) with typically 
lobated nuclei seen in a Nodular lymphocyte predominant Hodgkin lymphoma. 
for therapeutic purposes. Preliminary studies have shown that these immunotoxins have 
remarkable cytotoxic activity (Falini et al., 1992; Foyil & Bartlett, 2010; Tazzari et al., 1992). 
CD15, characteristic but not specific for H/RS, is detected in about 80% of cHL patients 
(Ascani et al., 1997; Foyil & Bartlett, 2010; Pileri et al., 1991; Pileri et al., 1995). H/RS cells 
usually lack CD45 (Falini et al., 1990; Filippa et al., 1996; Korkolopoulou et al., 1994), 
whereas B and, to lesser extent, T cell markers are seen in a proportion of cases. In 
particular, CD20 is found in 30%–40% of cHL cases (usually EBV negative) (Filippa et al., 
1996), and CD79a is found even less often (Tzankov et al., 2003a; Tzankov et al., 2003c; 
Watanabe et al., 2000). Positivity (usually weak) for one or more T cell marker is detected in 
a minority of cases in H/RS cells (Casey et al., 1989; Falini et al., 1987). Under these 
circumstances, single cell PCR studies have shown T-cell receptor (TCR) gene 
rearrangement in only three instances, with clonal Ig gene rearrangements occurring in most 
cHL cases with T-cell marker expression (Marafioti et al., 2000; Muschen et al., 2000). In 
contrast to that seen in NLPHL, the elements of cHL show variable expression of the BCL6 
molecule (Stein et al., 2008b). Antibodies against the nuclear-associated antigens Ki-67 and 
proliferating cell nuclear antigen (PCNA) stain most H/RS cells, suggesting that a large 
number of neoplastic cells enter the cell cycle (Gerdes et al., 1987; Sabattini et al., 1993).  
NLPHL differs greatly from the common type in terms of morphology, phenotype, 
genotype, and clinical behavior (Piccaluga et al., 2011). The only feature shared by NLPHL 
and cHL is the low number of neoplastic cells. The neoplastic population consists of large 
elements called lymphocytic/histiocytic or popcorn cells (Figure 1B) (Mason et al., 1994). 
However, these neoplastic cells have a characteristic profile, which differs greatly from that 
of cHL (Anagnostopoulos et al., 2000; Harris et al., 2000; Harris et al., 1994). In particular, 
they are CD45+, CD20+, CD22+, CD79a+, J chain+/−, EMA+/−, and CD15−.  CD30 positivity is 
rare and, when detected, weak. Popcorn cells regularly express the transcription factor 
OCT2 and its coactivator BOB.1 (Stein et al., 2001). Although NLPHL is characterized by a 
more preserved B-cell phenotype compared to the classical variant, a certain degree of 
defectivity was also described since a downregulation of several markers associated with 
the B-cell lineage (CD19, CD37, CD79b, and LYN) and with the germinal center maturation 







cHL, NLPHL has a higher age of onset (30-40 years), a higher incidence in males, a tendency 
for peripheral distribution, lack of B symptoms in the majority of cases, and mostly early-
stage disease (Diehl et al., 1999; Nogova et al., 2008).  
3. Clinicobiological prognostic parameters  
The high curability rates of HL coupled with increasing awareness of late treatment related 
morbidity, especially in young population, has highlighted the importance of some 
clinicobiological risk factors that might guide the therapeutical strategies. Although these 
factors are probably the clinical translation of some alterations at the molecular  level, to 
date there exist global consensus based upon these clinicobiological characteristics in order 
to decide the total amount of treatment to administer to every single patient, especially with 
respect to the type and number of cycles of chemotherapy, and thus to apply more intensive 
treatments to those cases with higher risk of relapse and, on the contrary, to avoid 
unnecessary treatment in patients with good prognosis. 
3.1 Staging and clinical risk categories 
Selection of treatments depends on initial risk stratification. In this sense, stage remains the 
most important factor in the initial approach for treatment of HL, being the Ann Arbor 
system with Cotswolds modifications the current staging system used for patients with HL 
(Table 1) (Diehl et al., 2004). 
 
Stage I — Involvement of a single lymph node region (I) or of a single extralymphatic organ 
or site (Ie). 
Stage II — Involvement of two or more lymph node regions on the same side of the 
diaphragm alone (II) or with involvement of limited, contiguous extralymphatic organ or 
tissue (IIe). The number of anatomic regions should be indicated by a subscript  
Stage III — Involvement of lymph node regions or lymphoid structures on both sides of the 
diaphragm (III) which may include the spleen (IIIs) or limited, a contiguous extralymphatic 
organ or site (IIIe) or both (IIIes). This may be subdivided into stage III-1 or III-2: stage III-1 
is used for patients with involvement of the spleen or splenic hilar, celiac or portal nodes; 
and stage III-2 is used for patients with involvement of the paraaortic, iliac, inguinal, or 
mesenteric nodes. 
Stage IV — Diffuse or disseminated foci of involvement of one or more extralymphatic 
organs or tissues, with or without associated lymphatic involvement. 
Table 1. Ann-Arbor/Costwolds staging system. 
In clinical practice, HL is classified in early and advanced disease (Connors, 2005). Early 
disease includes stages I-II and it is generally divided into favorable and unfavorable 
categories based upon the presence or absence of certain clinical features, such as age, 
erythrocyte sedimentation rate (ESR), B symptoms, and large mediastinal adenopathy. 
Cooperative research groups have used diverse definitions of favorable and unfavorable 
prognosis disease (Table 2) (Specht & Hasenclever, 1999). 
However, probably the most commonly used definition of favorable/unfavorable disease is 
the one proposed by the European Organization for the Research and Treatment of Cancer 
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(EORTC). Patients with one of the risk factors mentioned above are considered to have 
unfavorable prognosis early stage HL. This stratification is highly pertinent and useful since 
patients with favorable prognosis disease may have acceptable outcomes with less intensive 
therapy than that required for those with unfavorable prognosis early stage or advanced 
stage disease (Engert et al., 2010).  
 
EORTC: age 50 or older; large mediastinal adenopathy; with an ESR of more than 50/h and 
B symptoms (or with an ESR of more than 30 mm/h in those who have B symptoms); and 
disease with four or more regions of involvement  
GHSG: Three or more sites of disease; extranodal extension; mediastinal mass measuring 
one-third the maximum thoracic diameter or greater; and ESR more than 50 mm/h (more 
than 30 mm/h if B symptoms present)  
NCCN: large mediastinal adenopathy; bulky disease lager than 10 cm; B symptoms; ESR 
more than 50 mm/h; and disease with four or more regions of involvement 
NCI-C: age 40 or older; ESR more than 50 mm/h; and disease with four or more regions of 
involvement 
Table 2. Definitions of unfavorable disease by different cooperative research groups. 
Among patients with advanced stage HL (stage III/IV, and for some groups stage II plus 
bulky nodal disease), prognosis is largely determined by the International Prognostic Score 
(IPS) (Hasenclever & Diehl, 1998). The IPS was created by the IPS Project on Advanced 
Hodgkin's Disease based upon the total number of seven potential unfavorable features at 
diagnosis: serum albumin less than 4 g/dL, hemoglobin less than 10.5 g/dL, male gender, 
age over 45 years, stage IV disease, white blood cell count ≥15,000/microL, and lymphocyte 
count less than 600/microL and/or less than 8 percent of the white blood cell count.  
In this system, one point is given for each of the above characteristics present in the patient, 
for a total score ranging from zero to seven, representing increasing degrees of risk. When 
applied to an initial group of 5141 patients with HL treated with combination chemotherapy 
ABVD-like with or without radiotherapy, event-free survival rates at five years correlated 
well with IPS (Table 3) (Hasenclever & Diehl, 1998).  
 
No factors —84% (7 percent of patients) 
One factor — 77% (22 percent of patients) 
Two factors — 67% (29 percent of patients) 
Three factors — 60% (23 percent of patients) 
Four factors — 51% (12 percent of patients) 
Five or more factors — 42% (7 percent of patients)  
Table 3. Event free survival correlated with IPS. 
Consequently, different treatment policies are indicated upon the presence of these 
clinicobiological parameters, with application of more aggressive approaches when more 
risk factors are present.  
3.2 Positron Emission Tomography (PET) and correlation with clinical outcomes 
In the last years, F fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) has 






the course of antineoplastic therapy. Monitoring clinical evolution with PET is emerging as a 
new powerful predictor of outcome that can eventually diminish the amount of treatment to 
administer, sparing unnecessary cycles of chemotherapy or radiotherapy, or, on the 
contrary, making advisable the indication of more intensified treatments.  
Some trials have revealed that interim PET scans after one to three cycles of chemotherapy 
may predict long term outcomes in HL (Hutchings et al., 2005). In a prospective trial 
including 260 patients with advanced HL treated with ABVD, PET scans were made per 
protocol after 2 cycles of treatment (Gallamini A et al, 2007). This study demonstrated that 
patients with an interim negative PET scan had excellent prognosis, with two year event free 
survival rates of 95%, compared with 13% in those cases with PET positive. On multivariate 
analysis, interim PET status was the only significant prognostic factor, showing superiority 
over the classical IPS model (Gallamini et al., 2007). 
After these findings, next question is how to incorporate the interim PET results in the 
global management of treatment of HL in order to tailor a risk-adapted treatment strategy to 
the individual patient. There are several prospective trials ongoing in the United States and 
in Europe in early and advanced disease, testing different therapeutic approaches 
depending on PET scan findings. Their results are eagerly awaited to definitely establish 
finer tune therapeutic strategies in this disease. 
4. Role of virus in HL 
A negative association has been observed between HL and repeated early common 
infections (Rudant et al., 2010). Viruses are etiologically associated with a significant number 
of human leukaemia/lymphomas. Recognition of virus involvement in these malignancies 
is important as prevention of infection can lead to a reduction in the number of individuals 
at risk of disease. Early epidemiologic data suggested that HL develops among persons with 
a delayed exposure to a ubiquitous infectious agent such as Epstein-Barr virus (EBV) or 
among persons with acquired less common new infections such as human deficiency virus 
(HIV). The role of mediators of immunity genes may be important in the lack of adequate 
immune control of infectious agents. Several cytokines and interleukins are produced by 
neoplastic cells in lymphomas. 
EBV, a  herpesvirus with a worldwide distribution,  is present in H/RS cells of 40%–60% of 
cHL lesions and contributes to their pathogenesis (Kapatai & Murray, 2007; Khan, 2006). 
EBV positivity is higher with MCHL (60-70%) than with NSHL (15-30%). EBV+ H/RS cells 
express the latent membrane proteins 1, 2A y 2B (LMP1, LMP2A, LMP2B), the EBV nuclear 
antigens 1 (EBNA1), and the EBER RNAs, but consistently lack EBNA2 (latency II) (Jarrett, 
2002, 2006). LMP1 is likely to contribute to survival and proliferation of H/RS cells through 
activation of NF-κB and AP-1 (Kilger et al., 1998; Lam & Sugden, 2003). The role of LMP2A 
is more difficult to predict. Although LMP2A can deliver a survival signal in B-cells, H/RS 
cells have down-regulated many B-cell specific molecules including intracellular 
components involved in this signaling pathway (Kilger et al., 1998; Schwering et al., 2003). 
LMP2A may indeed contribute to this ‘loss of B-cell signature’, since cDNA microarray 
analysis of LMP2A expressing B-cells reveals a similar pattern of downregulated genes 
(Portis et al., 2003). It is also possible that EBNA1 and the EBERs contribute to the rescue of 
H/RS cells from apoptosis (Kennedy et al., 2003; Young & Rickinson, 2004). 
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Immunologic reactions (cytotoxic responses) against EBV can occur in the peripheral blood of 
some cHL patients (Khan, 2006). It has been estimated that EBV-specific T-cells might 
constitute up to 5% of circulating CD8+ T-cells (Hislop et al., 2002; Rickinson & Kieff, 2001). 
The intratumoral immunological alterations induced by EBV+ H/RS cells remain unclear.  The 
abnormal network of cytokines/chemokines and/or their receptors in H/RS cells is involved 
in the attraction of many of the microenvironmental cells into the lymphoma background. 
There is increasing evidence suggesting a change in the balance between Th1 and Th2 cells in 
the pathogenesis of HL and that this change induces reactivation of latent viral infections, 
including EBV. For example, interleukin like IL-1  is produced by H/RS cells in culture (Hsu 
et al., 1989) and IL-3 have demonstrated to present significant biological activity as growth and 
antiapoptotic factor for H/RS cells (Aldinucci et al., 2005). Serum levels of the receptor 
antagonist IL-1 (IL-1r ) are elevated in HL patients, patients with B symptoms have 
significantly lower levels of IL-1r than those without symptoms (Gruss et al., 1992). IL-10 is a 
pleiotropic cytokine that protects hematopoietic cells from apoptosis induced by 
glucocorticoids and doxorubicin. H/RS cells express functional IL-10 receptors and elevated 
IL-10 levels may inhibit apoptosis of H/RS cells. Elevated serum IL-10 levels have been found 
in up to 50% of HL patients and have been associated with inferior failure free survival (FFS) 
and overall survival (OS) in patients treated with ABVD or BEACOPP chemotherapy (Rautert 
et al., 2008; Sarris et al., 1999; Vassilakopoulos et al., 2001; Viviani et al., 2000). Elevated serum 
IL-10 levels confer a poor survival and may add to the prognostic value of the IPS in prediction 
of outcomes in HL (Axdorph et al., 2000). CCL17/TARC is a chemokine secreted by H/RS 
cells and its chemotactic properties may explain the infiltration of reactive T lymphocytes in 
HL (Niens et al., 2008; Peh et al., 2001; van den Berg et al., 1999).  Elevated CCL7/TARC levels 
have been seen in the majority of patients with HL (Niens et al., 2008). Persistent elevation of 
TARC after completion of treatment has been associated with poorer survival and could be 
important for treatment monitoring (Hnatkova et al., 2009; Weihrauch et al., 2005). EBV-
infected H/RS cells were shown to stimulate also the stromal production of particular 
chemokines such as the interferon-inducible chemokine IP-10 (CXCL10) (Teichmann et al., 
2005), Rantes/CCL5 (Aldinucci et al., 2008; Fischer et al., 2003), the ligand CCL28 (Hanamoto 
et al., 2004),  CCL20 that is capable of attracting regulatory T cells (Baumforth et al., 2008) and 
the macrophage-derived chemoattractant (MDC)/CCL22 (Niens et al., 2008). It has been also 
suggested that immunologic reactions against EBV can occur in the peripheral blood of some 
cHL patients (Khan, 2006). However, no comprehensive characterization of intratumoral 
immunologic alterations induced by EBV+ H/RS cells has been described so far. EBV was 
shown to contribute to HL patients survival (Kapatai & Murray, 2007). The observation of 
Th1/antiviral response in EBV+ cHL tissues provides a basis for novel treatment strategies 
(Chetaille et al., 2009; Skinnider & Mak, 2002). 
Although HL is not considered an acquired immunodeficiency syndrome (AIDS)-defining 
neoplasm, HIV-infected patients treated with highly active antiretroviral therapy (HAART) 
present a higher incidence of HL compared with the population without HIV infection 
(Powles & Bower, 2000; Powles et al., 2009). Almost 100% of HIV-associated cases are EBV-
positive and, in these patients, EBV is found more frequently in H/RS cells (Powles & 
Bower, 2000). HIV-HL exhibits pathological features that are different from those of HL in 
‘‘general population’’(Carbone et al., 2009; Grogg et al., 2007) while is characterized by the 
predominance of unfavorable histological subtypes (MCHL and LDHL) (Carbone et al., 






is the widespread extent of the disease at presentation and the frequency of systemic B-
symptoms. At the time of diagnosis, 70–96% of the patients have B-symptoms, and 74–92% 
have advanced stages of disease with frequent involvement of extranodal sites, the most 
common being bone marrow (40–50%), liver (15–40%), and spleen (around 20%) (Tirelli et 
al., 1995). The widespread use of HAART has resulted in substantial improvement in the 
survival of patients with HIV infection and lymphomas because of the reduction of the 
incidence of opportunistic infections and the opportunity to allow more aggressive 
chemotherapy. Moreover, the less-aggressive presentation of lymphoma in patients treated 
with  HAART compared with untreated patients may also favorably change the outcome for 
HIV-infected patients with lymphomas (Vaccher et al., 2003).  In fact, compared with 
patients who never received HAART, patients in HAART before the onset of cHL generally 
are older, have less B-symptoms, and a higher leukocyte and neutrophil counts and 
hemoglobin level (Chimienti et al., 2008). 
5. Antitumoral immunity 
Tumors are more than an accumulation of neoplastic cells; they might be more properly 
considered as a functional tissue immunologically mediated and formed by a complex tissue 
network in which neoangiogenesis, infiltrating immune competent cells, stromal cells, and a 
differentiated and specific extracellular matrix constitute the tumor microenvironment with 
the capacity of regulating cancer development (Alvaro et al., 2010; Tlsty & Coussens, 2006). 
The interplay between the host immune system, malignant cells, and all other components 
of tumoral stroma determine proliferation, invasion, angiogenesis, and remodelling of 
extracellular matrix and metastasis. 
The hypothesis of immunesurveillance postulates that one of the principal functions of the 
immune system would be recognizing neoplastic cells and eliminating them before they 
form tumors (Burns & Leventhal, 2000). In these conditions, the absence of an effective 
immune system increases the risk of developing cancer. If the immune system is a complex 
system of different types of cells and molecules whose primary function is to act as an 
effective tumor suppressor, it is certain that the system may behave inefficiently, as 
indicated by the fact of tumors in immunocompetent individuals. Thus, in addition to the 
concept of immunosurveillance arises of immunostimulation (Ichim, 2005). Although 
various mechanisms could induce immunosuppression (virus, transplant ..), the increasing 
likelihood of cancer (Burnet, 1957) in immunologically intact individuals suggests that the 
immune response might not only be ineffective but may itself contribute to tumor 
progression (Prehn, 1972). That is, the immune system has the ability to act as a double-
edged sword, indicating that tumor elimination requires a good coordination of the various 
elements of the immune system. 
The products of mutated or deregulated genes of tumoral cells contribute to the growth and 
invasion of tumoral cells, as well as to the expression of proteins with the ability to stimulate 
the immune response. The immunogenic capacity of the tumor can be evaluated by means 
of the study of the reactive infiltration, which is mainly composed by innate immune cells. 
The nature, function and specificity of the effector cells that drive the antitumoral immune 
response have been widely studied. Innate immunity is represented essentially by dendritic 
cells (DCs), macrophages, natural killer (NK), NK/T cells, neutrophils, cytokines and 
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complement proteins, whereas adaptive immune cells are represented by B lymphocytes, 
CD4+ T-helper lymphocytes and CD8+ cytotoxic lymphocytes (CTL). The general 
mechanisms for tumor suppression have been principally attributed to CD4+ T helper 
lymphocytes. Cytokines and lymphokines from CD4+ T cells can also activate CD8+ CTL, 
NK cells and macrophages, which have all been shown to be involved in tumor immunity 
(Adam et al., 2003; Gonthier et al., 2004; Ikeda et al., 2002; Peipp & Valerius, 2002; Smyth et 
al., 2002). Immunoregulatory cytokines such as IL-10 and TGF- play an important role in 
immune tolerance, and it seems that suppressor effect of regulatory T cells (CD4+CD25+) on 
the development of tumor associated antigen-reactive lymphocytes is independent of 
cytokines (Aldinucci et al., 2005).  Contributing to the complexity of the interactions between 
the reactive background and malignant cells, immune cells present in the local infiltrate 
have proved capable of modulating apoptosis and of inducing proliferation of tumoral cells 
via death receptors, cytotoxic granule liberation, and withdrawal of growth factors or 
production of immunosuppressive cytokines (Atkinson & Bleackley, 1995; Berke, 1995; de 
Visser & Kast, 1999; Skinnider & Mak, 2002). The efficacy of tumoral–immune cells 
interactions depends on several factors, such as the expression of MHC class I molecules 
and immunogenic epitopes in tumoral cells, the type of immune cell and the accessibility of 
tumor cells.  
Tumor antigens recognized by T cells (generally CD8+ lymphocytes) represent the principal 
target of antitumoral immunity and are presented by MHC class I molecules; that is to say, 
that tumoral cells behave as antigen presenting cells (APC), presenting their own antigens to 
T cells. Naturally, professional APC can also present antigens to CD4+ lymphocytes through 
MHC class II molecules (Quezada et al., 2010). Dendritic cells (DC) and other APC are 
dispersed between tissues as sentinels or alarm systems ready to detect the presence of 
foreign antigens. While in the tumor microenvironment IL-12 production tends to be 
suppressed, resulting in a decrease in Th1 activity, DCs represent probably the most 
important regulators of naïve T cells, with a great capacity to produce and release IL-12. In 
their process of polarization, DCs are under the influence of inflammatory mediators such 
as prostaglandins produced by macrophages, fibroblasts, and tumor cells. A new route of 
junction between innate and adaptive immunity through the interaction between DC and 
NK cells has been suggested (Adam et al., 2005). Actually, at least four distinct CD4 T cells 
subsets have been described: Th1, Th2, Th17, and regulatory T cells, each one with a unique 
cytokine secretion pattern and function (Zhu & Paul, 2008). Their primary roles is providing 
cytokines for the development of CTL, in addition to being able to secrete tumor necrosis 
factor (TNF) and interferon (IFN)-gamma, which can increase the expression of MHC class I 
by the tumor cell and therefore increase its sensitivity to CTL lysis. Among natural CTL, 
natural killer cells (NK cells) can be activated directly by contact with the tumor or as a 
result of the stimulus provided by cytokines. In addition, lymphokine-activated killer cells 
(LAK) are a group of NK cells derived from peripheral blood cells or tumor infiltrating 
lymphocytes (TIL) in patients with high concentrations of IL-2 and show a high capacity, 
nonspecific in this case, to lyse tumor cells. Others cellular mediators such as the 
macrophages are also capable of lysing tumor cells by releasing a large amount of lysosomal 
enzymes and reactive oxygen metabolites. Once activated they also produce cytokines such 
as TNF that exerts its cytotoxic activity triggering apoptosis in a similar way to that 






6. Molecular markers 
In HL, a striking feature of both NLPHL and cHL entities is that the malignant cells account 
for only around 1% of the tumor mass (Stein et al., 2008a). However, notable significant 
differences exist between these entities in terms of natural history, relation to EBV, cell 
morphology, phenotype, molecular characteristics, and clinical behavior (Farrell & Jarrett, 
2011; Maggioncalda et al., 2011). 
There is compelling evidence that H/RS cells are clonal B cells that have lost their B cell 
phenotype. Effectively, H/RS cells, from nearly all cHL cases, and malignant popcorn cells 
from NLPHL have detectable rearrangements of Ig heavy and⁄or light chain genes, 
confirming a B cell origin (Kuppers et al., 1996; Kuppers et al., 1994) and, in any given case, 
the rearrangements are identical, proving the clonal nature of the disease (Kanzler et al., 
1996; Kuppers et al., 1994; Marafioti et al., 2000). Furthermore, the Ig variable (IgV) gene 
regions show evidence of somatic hypermutation, revealing a GC or post-GC origin 
(Kuppers, 2002). It was also suggested that cHL and B cell non-Hodgkin lymphoma (BNHL) 
arisen from a common precursor (pre-GC or GC B cell) since both generally harbor identical 
IgV gene rearrangements but have distinct somatic Ig gene mutations (Brauninger et al., 
2006). Intraclonal IgV gene diversity is observed in popcorn cells, indicating ongoing 
somatic hypermutation, whereas identical somatic hypermutations were observed in H/RS 
cells indicating a later stage of B cell differentiation (Kanzler et al., 1996; Kuppers et al., 1994; 
Marafioti et al., 2000). Around 25% of cHL cases present non-functional Ig genes due to 
“crippling” mutations (Brauninger et al., 2006; Kanzler et al., 1996; Kuppers et al., 1994; 
Kuppers et al., 2001). H/RS cells harbor uncommonly rearranged T cell receptor genes 
(<2%), suggesting a T cell origin in a small minority of cases (Muschen et al., 2001; Muschen 
et al., 2000; Seitz et al., 2000). At phenotypic level, markers of B lineage (CD20, CD19, CD79, 
surface Ig) and transcription factors (OCT2, BOB1 and PU1) are generally down-regulated in 
H/RS cells (Hertel et al., 2002; Schwering et al., 2003), and expression of the B cell-specific 
transcription factor PAX5 is usually retained (Foss et al., 1999). In contrast, popcorn cells 
express B cell markers including CD20, CD79, PAX5, OCT2 and BOB1. The global 
suppression of the B cell signature results from transcriptional reprogramming (Kuppers et 
al., 2003; Mathas et al., 2006; Nie et al., 2003; Renne et al., 2006; Smith et al., 2005; Ushmorov 
et al., 2006; Ushmorov et al., 2004).  
Mature B cells lacking B cell receptors would normally die by apoptosis, and therefore 
H/RS cells must have developed mechanisms to facilitate survival. The escape from 
apoptosis and transcriptional reprogramming of H/RS cells are interlinked and seem 
important to disease pathogenesis. EBV gene products appear to contribute to H/RS cell 
survival, proliferation and reprogramming through dysregulation of several signaling 
networks and transcription factors such as intrinsic overexpression of CD30 (Horie et al., 
2002), deleterious mutations of the genes encoding IB proteins (IB(Emmerich et al., 
1999; Emmerich et al., 2003; Jungnickel et al., 2000; Lake et al., 2009; Wood et al., 1998) and 
amplification of the chromosomal region including the c-Rel gene (Barth et al., 2003; Joos et 
al., 2002; Martin-Subero et al., 2002). In cHL EBV-associated cases, the virus can contribute 
directly to activation of NF-B though its protein latent membrane protein 1 (LMP-1), which 
mimics CD40 signaling. Mutations of genes encoding inhibitors and regulators of NF-B 
such as inactivating mutations of the TNF- induced protein 3 (TNFAIP3) gene have been 
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detected in a large proportion of EBV-negative cases (Kato et al., 2009; Schmitz et al., 2009). 
Others genomic lesions affecting different signaling pathways in H/RS cells (JAK-STAT, 
PI3K–Akt–mTOR, MAPK–MEK–ERK and AP1–Jun⁄Fos) have also been demonstrated 
(Dutton et al., 2005; Emmerich et al., 1999; Joos et al., 2003; Juszczynski et al., 2007; Kube et 
al., 2001; Skinnider et al., 2002; Weniger et al., 2006; Zheng et al., 2003). In cHL and primary 
mediastinal B-cell lymphoma, genomic breaks of the major major histocompatibility 
complex (MHC) class II transactivator CIITA have been demonstrated to be highly recurrent 
(15% and 38% respectively) (Steidl et al., 2011b). The functional consequences of CIITA gen 
fusions is the downregulation of surface HLA class II expression and overexpression of 
ligands of the receptor molecule programmed cell death 1 (CD274/PDL1 and 
CD273/PDL2). These receptor-ligand interactions have been shown to impact anti-tumour 
immune responses in several cancers, whereas decreased MHC class II expression has been 
linked to reduced tumour cell immunogenicity.  
Several of these recurring genetic lesions appear correlated with disease outcome (Slovak et 
al., 2011). Nonrandom DNA copy number alterations in cHL (H/RS cells CD30+) have been 
identified in the molecular karyotypes of cHL as comparing with the genomic profiles of GC 
B cells. Frequent gains (>65%) were associated with growth and proliferation, NF-κB 
activation, cell-cycle control, apoptosis, and immune and lymphoid development. Frequent 
losses (>40%) observed encompassed tumor suppressor genes, transcriptional repressors 
and SKP2 (Slovak et al., 2011).  
Thus, multiple transcriptional and signaling pathways are disrupted in HL, and are thought 
to cooperate to increase H/RS cell proliferation, reduce apoptosis and promote a favorable 
cellular microenvironment through the release of multiple cytokines and chemokines. These 
findings may be useful prognostic markers in the counselling and management of patients 
and for the development of novel therapeutic approaches in primary refractory HL.  
7. Biological factors: Immune response in HL  
The tumor microenvironment consists of a specific mixture of immune cells that express a 
distinctive profile for each tumor type, from which the efficacy of the immune response 
against the tumor is eventually derived (Alvaro et al., 2009). Exist increasing evidence of the 
importance of the microenvironment in the molecular pathogenesis of HL (Steidl et al., 
2011a), and a promising therapeutic target has been raised focused on this approach. The 
presence of a characteristically rich inflammatory background particularly distinguishes HL 
from other lymphoproliferative syndromes. Differences in gene expression profiles of 
malignant cells in lymphoproliferative syndromes do not always determine the 
aggressiveness of the lymphoma, while recent contributions determine that HL represents 
the prototypical tumor in which the interplay between H/RS and the reactive 
microenvironment determines not only the histological morphology and classification but 
also the clinicopathological features and prognosis of these patients. Quantitative analysis of 
infiltrating immune cells reveals undisclosed relationships between the relative proportion 
of these cells and HL clinical outcome, illustrating how factors other than tumoral 
cellularity, or the immunophenotype and molecular anomalies present in the H/RS cells, 






7.1 Patterns of immune response in HL and prognosis 
An abnormal pattern with overexpression of cytokines and their receptors is characteristic in 
H/RS cells. This pattern explains the abundant mixture of inflammatory cells, stromal 
changes and the predominance of Th2 cells between the various subpopulations of 
lymphoid cells in the tumoral microenvironment of HL (Swerdlow et al., 2008b). A 
predominance of CD4+ T lymphocytes in the background of tumoral cells in addition to a 
high number of cytotoxic cells (CD8, CD57, TIA-1) has been observed in the majority of HL-
tissues (Figure 2) (Alvaro-Naranjo et al., 2005; Oudejans et al., 1997; Poppema et al., 1998).  
 
Fig. 2. Immunohistochemical staining of inflammatory background in HL: T lymphocytes 
(CD4 and CD8), NK cells (CD56 and CD57) and cytotoxic cells (GrB and TIA-1).  
Regardless of the classic clinical and pathological features, a high proportion of infiltrating 
CD8+ and CD57+ cells as well as a low number of infiltrating CTL (evaluated by the presence 
of Granzyme B and TIA-1) appear to be associated with a favorable outcome for HL patients 
(without B symptoms and lower clinical stages) and better response to treatment (Alvaro-
Naranjo et al., 2005; Alvaro et al., 2005; Ansell et al., 2001). It is unclear to date whether the 
presence of CD8+ T cells correlates with the antitumor cytotoxic response. Nevertheless, it 
has been suspected that CD8+ T cells may be recruited in an antigen-non-specific mode in 
HL (Willenbrock et al., 2000).  
Although the activation status of infiltrating cells have been demonstrated to be 
independent of the degree of malignancy in HL (Bosshart, 2002), others studies have shown 
that the presence of activated cytotoxic T cells (granzyme B+) is associated with unfavorable 
follow-up in these patients (Kanavaros et al., 1999; Oudejans et al., 1997; ten Berge et al., 
2001). A higher level of not activated cytotoxic cells (TIA-1+) has been observed in advanced-
stage cHL without prognostic value (Camilleri-Broet et al., 2004). However, TIA-1+ CTL 
associated with the presence of regulatory T cells FOXP3+ appears to play an important role 
in monitoring HL patients (Alvaro et al., 2005). Variations in the level ofcytotoxic TIA-1+ and 
regulatory T cells observed during the course of the disease could be implicated in the 
progression of HL (Alvaro et al., 2005).  
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Fig. 3. Representation of the two immune patterns observed in HL significantly associated 
with their clinicopathological features. The immunesurveillance pattern (A) with a high 
proportion of infiltrating T lymphocytes, NK cells, DCs, activated CTL but low proportion 
of resting CTL and TAM is associated with a favorable outcome. The immune escape 
pattern (B) with a high proportion of infiltrating resting CTL and TAM, but low proportion 
of T lymphocytes, NK cells, DCs and activated CTL is associated with an unfavorable 
outcome. MC, mixed celularity; NS, nodular sclerosis; CR, complete response.  
Association of tumor-associated macrophages (TAM) CD68+ with adverse clinical outcomes 






Recently, a gene expression profile analysis performed on 130 biopsy samples from patients 
with HL identified a signature of TAM and monocytes that was predictive of treatment 
failure (Steidl et al., 2010). In this study the sensitivity and specificity of this GEP signature 
for outcome in this cohort was greater than that of the International Prognostic Score (IPS). 
After these findings, biopsy samples from an independent cohort of 166 patients were 
evaluated with immunohistochemistry for the presence of CD68 expressing macrophages 
using a score from 1 to 3, from lower to higher infiltration (Steidl et al., 2010). When 
compared with those with low CD68 expression, patients with tumors that demonstrated an 
increased number of CD68 expressing macrophages had shorter median progression-free 
survival (PFS), lower rate of 10-year disease-specific survival (60 versus 89%), and higher 
failure rate of secondary treatment with curative intent (63 versus 13%). It has been also 
recently demonstrated that high level of CD68 correlated with poorer survival, event-free 
survival (EFS) and with the presence of EBV in the tumor cell population (Kamper et al., 
2011). These results suggest a new pathological prognostic factor to be considered, however 
it is unclear at this time how CD68 status should affect patient management.   
A plausible explanation for the extensive inflammatory infiltrate present in HL secretion could 
be a variety of cytokines produced by both tumor cells and surrounding stromal tissue. CD4+ 
T cells produce Th2 cytokines that could contribute to local suppression of the cellular immune 
response mediated by Th1. However, the categorization of CD4+ T cells in Th1 and/or Th2 is 
an oversimplification (Marshall et al., 2004) as regulatory T cells with CD4+CD25+ phenotype 
not only play a regulatory role of autoimmunity, but also have suppressive effects on the 
development of antigen-reactive lymphocytes associated with the tumor (Wei et al., 2004). The 
H/RS cells secrete high amounts of chemokine, thymus and activation-regulated chemokine 
(TARC) and macrophages-derived chemokine (MDC) in particular, which attract lymphocytes 
expressing CCR4 receptor, such as Th2 (Skinnider & Mak, 2002). These cytokines may 
contribute to the pathogenesis of the disease initiated and sustained the presence of the 
reactive infiltrate. Alternatively, immune cells can produce cytokines responsible for 
proliferation and survival of tumor, producing a positive feedback between the tumoral cells 
and immune system. The composition of the infiltrate may also differ depending on the state 
of immunosuppression of HL patients. Moreover, HIV infection affects, for direct or indirect 
mechanisms, both reactive changes as neoplastic lymphoid tissue. Recently we have seen a 
significant loss of intratumoral T cells CD4+ (CD4/CD8 ratio reversal) and a decrease in 
intratumoral activated CTL in patients with HIV-infected HL (Bosch Princep et al., 2005). A 
low proportion of CD4+ cells appears also to be significantly related to EBV status, probably 
due to the relation with the local tumor-associated suppression of EBV-specific T-cell 
responses observed in EBV+ HL cases (Frisan et al., 1995).   
7.2 Immune response regulation in HL 
Tumors employ a plethora of immunosuppressive mechanisms, which may act in concert to 
counteract effective immune responses. Different mechanisms have been suggested to 
account for the CTL-mediated apoptosis resistance of H/RS cells, such as the 
downregulation of MHC class I molecules of the H/RS cells, prevention of recognition of 
tumor-associated antigens by CTLs (Poppema & Visser, 1994), or the local secretion of both 
IL-10 and transforming growth factor-b by H/RS cells (Newcom et al., 1988; Ohshima et al., 
1995), which are able to inhibit CTL function. In this respect, it appears that the blockage of 
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the Granzyme B pathway of apoptosis through the overexpression of serine protease 
inhibitor PI-9/SPI-6 is an important additional mechanism for immune escape by tumors 
(Medema et al., 2001). The expression of PI9 tends to be associated with a high percentage of 
activated CTLs, especially in HL (Bladergroen et al., 2002), suggesting that PI9 may play a 
role in protecting against Granzyme B-induced apoptosis, and partially explaining why 
tumors expressing high levels of PI9 have a particularly poor clinical outcome, irrespective 
of the number of Granzyme B+ cells in the inflammatory infiltrate. 
Different subsets of immune cells contribute also to this immunosuppressive network, 
including CD4+CD25+ regulatory T cells. In HL, it has been initially proposed that CD4+ T 
cells produce cytokines of Th2 type that could contribute to local suppression of the cellular 
immune response mediated by Th1 cells (Bladergroen et al., 2002; Poppema et al., 1999). 
However, the categorization of CD4+ T cells in Th1 and/or Th2 constitutes an 
oversimplification and it has been shown that regulatory T cells with CD4+CD25+ phenotype 
not only play a role in controlling autoimmunity, but also have suppressive effects on 
lymphocyte development tumor associated antigen reagents (Curiel et al., 2004; Fontenot et 
al., 2003; Suri-Payer et al., 1998). Functional and molecular characterization of these cells has 
been facilitated by the identification of markers such as FOXP3 and others (Shimizu et al., 
2002; Sutmuller et al., 2001; Takahashi et al., 2000). FOXP3 encodes a transcription factor 
known as Scurfina, specifically expressed by T cells CD4+CD25+(Karube et al., 2004), that 
acts converting naïve regulatory T cells CD4+CD25- phenotype to CD25+ (Hori et al., 2003). 
More recently, it was suggested that regulatory T cells and PD1+ T cells interact with H/RS 
cells (Alvaro et al., 2005; Teichmann et al., 2005; Yamamoto et al., 2008), which produce the T 
regulatory attractant galectin-1 and the PD-1 ligand, PDL-1 (Yamamoto et al., 2008). On the 
other hand, the observation of numerous CXCR3+ lymphocytes in some HL tumors has 
raised the possibility of an occasional Th1-predominant immune response (Alvaro-Naranjo 
et al., 2005).  
The regulatory T cells can inhibit the production of both IL-2 to regulate the high expression 
of IL-2Rα (CD25), ie, delay or block the activation of CD8+ cells and natural killer (NK) cells 
against tumor antigens (Azuma et al., 2003; Wolf et al., 2003). The immunosuppressive 
properties of regulatory T cells appear to be particularly important because of its large effect 
on cellular cytotoxicity represented by CTLs and NK cells. The presence of low numbers of 
FOXP3+ cells and a consequent high rate of TIA-1+ cells in the infiltrate represents an 
independent prognostic factor negatively affecting the survival of the disease. Furthermore, 
when the disease relapses and progresses, larger number of TIA-1+ cells and lower 
proportion of FOXP3+ on the reactive background of the tumor are also prone to be seen 
(Alvaro et al., 2005). 
8. Apoptotic and cell cycle pathways in HL 
The aberrant expression of proteins involved in regulation and execution of apoptosis and 
cell cycle of lymphocytes has been demonstrated in several types of lymphoma and the 
importance of the level of apoptosis and proliferation in clinically aggressive 
lymphoproliferative syndromes (Bai et al., 2005; Bai et al., 2003; Garcia et al., 2003; Sanchez-
Beato et al., 2003). These anomalies are probably not sufficient to explain the development of 
lymphomas, even if the effectiveness of therapy is presumed to be mediated by activation of 






controlling apoptosis and proliferation of H/RS cells and biological factors such as EBV 
detection, which influence the clinical aggressiveness of the disease (Bargou et al., 1997; 
Garcia et al., 1999; Hinz et al., 2002; Hinz et al., 2001; Izban et al., 2001; Kupper et al., 2001; 
Leoncini et al., 1997; Mathas et al., 2002; Montesinos-Rongen et al., 1999; Morente et al., 1997; 
Sanchez-Beato et al., 1996).  These studies have demonstrated alterations of the p53, Rb and 
p27 tumor suppressor pathways (Bai et al., 2005; Garcia et al., 1999; Guenova et al., 1999; 
Hinz et al., 2001; Lauritzen et al., 1999; Montesinos-Rongen et al., 1999; Morente et al., 1997; 
Sanchez-Beato et al., 1996; Sanchez-Beato et al., 2003; Tzardi et al., 1996), overexpression of 
cyclins involved in the G1/S and G2/M transition such as cyclins E, D2, D3, A and B1 
(Garcia et al., 2003; Kolar et al., 2000; Leoncini et al., 1997; Ohshima et al., 1999; Teramoto et 
al., 1999; Tzankov et al., 2003b), overexpression of cyclin-dependent kinases such as CDK1, 2 
and 6 (Garcia et al., 2003) and overexpression of the anti-apoptotic proteins c-FLIP, bcl-xl, c-
IAP2 and surviving (Brink et al., 1998; Garcia et al., 2003; Kanavaros et al., 2000; Kuppers, 
2002; Kuppers et al., 2003; Staudt, 2000; Thomas et al., 2004).  
These findings raised the questions of how H/RS cells escape apoptosis, acquire self-
sufficiency in growth signals and proliferate (Kuppers, 2002; Kuppers et al., 2003; Staudt, 2000; 
Thomas et al., 2004). The physiologic relevance of the deregulation of the cell cycle and 
apoptosis regulators in cHL could be related to the different probabilities of survival of HL 
patients. Many studies have analyzed the clinical relevance of the expression of cell cycle and 
apoptosis regulators in cHL using IHC or gene expression profiling (Brink et al., 1998; 
Devilard et al., 2002; Garcia et al., 2003; Montalban et al., 2000; Morente et al., 1997; Smolewski 
et al., 2000).  Shorter survival was significantly associated with high proliferation index (Ki67), 
high expression of bcl2, bcl-xl, bax and p53, low expression of Rb and caspase 3 and high 
apoptotic index (Montalban et al., 2004; Rassidakis et al., 2002a; Rassidakis et al., 2002b; Sup et 
al., 2005; Abele et al., 1997; Brink et al., 1998; Garcia et al., 2003; Montalban et al., 2004; Morente 
et al., 1997; Smolewski et al., 2000). Evidence has accumulated that the constitutive activation 
of the NF-B pathway in H/RS cells is of particular importance for explaining the apoptosis 
deregulation in cHL by up-regulating an anti-apoptotic gene expression program (Bai et al., 
2005; Hinz et al., 2002; Hinz et al., 2001; Mathas et al., 2002). By gene expression profiling, the 
good outcome cHL were characterized by up-regulation of genes involved in apoptosis 
induction (APAF, bax, bid, caspase 8, p53, TRAIL) and cell signaling, including cytokines and 
transduction molecules (IL-10, IL-18, STAT3), while the bad outcome cHL were characterized 
by upregulation of genes involved in cell proliferation (Ki67) and by down-regulation of 
tumor suppressor genes PTEN (Phospatase and Tensin homolog deleted on chromosome 10) 
and DCC (Deleted in Colorectal Cancer) (Devilard et al., 2002). 
Within the complexity of the interactions between the reactive substance and tumor cells, 
immune cells present in the infiltrate have been shown to modulate the apoptosis and 
proliferation of tumor cells via apoptotic receptors, cytotoxic granule release, growth factors 
or immunosuppressive cytokines (Atkinson & Bleackley, 1995; Berke, 1995; de Visser & 
Kast, 1999; Famularo et al., 1994; Hahne et al., 1996). IHC study has demonstrated that the 
antiapoptotic profile observed in H/RS cells is associated with a general increase in CD4+ T 
cells infiltrating (related to Bcl-XL and Mcl-1) and an overall decline CD8+ T lymphocytes 
infiltrating, NK cells and dendritic cells (related to Bcl-XL and Bax) (Alvaro et al., 2008). 
Alterations observed in the G1-S checkpoint of H/RS cell cycle, in the principal tumor 
suppressor pathways Rb-p16INK4a and p27KIP1, and the high rate of proliferation (MIB1, 
BCL6) are also strongly associated with higher infiltration of the overall immune response 
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against the tumor (Alvaro et al., 2008). These results point to the regulation of proteins 
involved in apoptosis and proliferation of tumor cells by direct interactions between these 
cells and the surrounding inflammatory microenvironment.  
These infiltrated cells are able to activate apoptotic caspase proteolytic cascade through TNF 
receptor superfamily interactions (FasL/Fas and CD40/CD40L). The different members of 
this superfamily share common cell signaling pathways that mediate the activation of 
nuclear factor NF-κB and mitogen-activated protein kinases. In this case, CD40/CD40L 
interactions are known to induce the upregulation of Bcl-XL and Mcl1 expression and to 
mediate the activation of NF-B (Hinz et al., 2001; Hong et al., 2000; Inoue et al., 2000; Kater 
et al., 2004; Lee et al., 1999; Metkar et al., 2001). CTLs are also able to trigger a second 
proapoptotic pathway through the protease granzyme B, which, once released from CTLs, is 
translocated into the target cell by perforin, where it activates the effector caspase cascade 
(Thome & Tschopp, 2001). On the other hand, the wide variety of cytokines and chemokines 
present in HL tumoral tissue (IL-2, IL-4, IL-6, and IL-13), responsible for the massive influx 
of activated immune cells (Poppema et al., 1999), has been shown to regulate the expression 
of the various members of Bcl2 family, such as the antiapoptotic Bcl2 homologues Bcl-XL 
and Mcl1 and the proapoptotic Bax (Akbar et al., 1996; Jourdan et al., 2000; Puthier et al., 
1999; Song et al., 2002; Tang et al., 2002).  
Likewise for the apoptotic markers, the physiologic signals present in the reactive 
microenvironment also interfere with components of the G1-CDK checkpoint (cyclin D3, 
CDK6, and p27) (Malumbres & Barbacid, 2001; Wagner et al., 1998). The constitutively 
activated NF-B has also been shown to induce changes in the expression of a set of proteins 
regulating cell cycle progression and gene transcription, including cyclin D1, p53, p16 
INK4a, and p27KIP1 (Hinz et al., 2001; Sanchez-Beato et al., 2003). Cytotoxic cells are able to 
induce directly the permanent down-regulation of p27KIP1, probably as a consequence of 
increased degradation mediated by SKP2, a ubiquitin ligase for p27KIP1 (Blanchard et al., 
1997; Ren et al., 2005; Wagner et al., 1998). Related with the heightened proliferative state in 
these tumors is the high level of expression of Bcl6, a multifunctional regulator that is able 
not only to down-regulate cyclin D2 and p27KIP1 expression (Shaffer et al., 2000) but also to 
repress Bcl-XL (Tang et al., 2002).  
The presence of EBV was significantly associated with the overexpression of STAT1 and 
STAT3. STAT3 was found to be associated with a low infiltration of CD4 T lymphocytes and 
a high infiltration of activated cytotoxic cells. Although STAT1 is considered to be a 
potential tumor suppressor (promoting apoptosis), STAT3 is thought to be an oncogene 
because it leads to the activation of cyclin D1 and Bcl-XL expression and is involved in 
promoting cell cycle progression and cellular transformation and in preventing apoptosis 
(Calo et al., 2003).  
The physiologic relevance of these relationships could be related to the different 
probabilities of survival of HL patients. Different sets of deregulated immune and tumoral 
genes have shown to be associated with a therapeutically unfavorable response in HL 
patients (Sanchez-Aguilera et al., 2006). For example, altered expression of bcl-2 and the bcl-
2 family of proteins (e.g., bcl-Xl, BAX) in H/RS cells may prevent apoptosis and explain 
resistance to treatment-induced apoptosis. Under these conditions, the concomitant analysis 
of the immune infiltrate and the apoptotic/proliferative pathways of tumoral cells should 






cell growth. Possible molecules that interfere with these molecular links, particularly some 
enzymes representative of the immune metabolic state or tumoral cell cycle (Sanchez-
Aguilera et al., 2006), might be pharmaceutically manipulated and could be candidates for 
new therapeutic targets pertinent to patient care.  
9. HL in immunosuppressed patients  
Epidemiologic and molecular findings suggest that cHL is not a single disease but consists 
of more than one entity and may occur in different clinical settings. According to the 
acknowledged international literature (Swerdlow et al., 2008a), cHL arises either in the 
general population (Stein et al., 2008a) but also in the immunosuppressed host, specifically 
in HIV-infected individuals (Raphael et al., 2008), and in post-transplant patients, most often 
in renal post-transplant patients (Swerdlow et al., 2008c). 
From a clinical perspective, HIV-infected HLs have some peculiarities. Firstly, it must be 
distinguished two eras, before and after the widespread use of highly active antiretroviral 
therapy (HAART) (Powles et al., 2009). Before HAART, HIV-HL patients were generally 
diagnosed with an aggressive presentation. Advanced stages were the rule at diagnosis with 
frequent involvement of extranodal sites, particularly bone marrow, liver and spleen. In 
addition, up to 95% of patients had systemic B symptoms when diagnosed, and 
consequently survival rates were extremely disappointing (Tirelli et al., 1995). Nevertheless, 
introduction of HAART have led to forms of presentation less aggressive, a dramatic 
reduction in the incidence of opportunistic infections, and finally it have allowed to 
complete curative treatment with chemotherapy in most of the patients (Carbone et al., 
2009). Regarding chemotherapy, optimal treatment for HIV-HL has not been definitely 
established due to the relatively low incidence of this disease. However, little phase II 
studies with few patients have found that, in this modern HAART era, standard ABVD 
treatment may be safely administered with or without growth-colony stimulating factors 
(G-CSF) support (Xicoy et al., 2007), although some groups argue in favor of G-CSF 
introduction from the beginning to minimize risks. Prophylaxis against Pneumocystis 
jiroveci infection with trimethoprim-sulfamethoxazole is also strongly recommended in all 
these patients. Other more intensive regimens like BEACOPP or Stanford V with 
consolidation radiotherapy have been tested with acceptable results in terms of complete 
responses (100% and 81%, respectively), although a higher incidence of opportunistic 
infections and hematologic toxicity were registered. Finally, even the use of high dose 
chemotherapy and autologous stem cell transplantation have been demonstrated feasible in 
HL-HIV relapsed patients with curative purposes (Carbone et al., 2009). To conclude, it 
must be said that clinical outcomes of patients with HIV-HL has improved after HAART 
introduction, with higher curability rates when a combined antineoplastic and antiretroviral 
strategy is followed and completed. 
Post-transplant lymphoproliferative disorders (PTLDs) are a heterogeneous group of 
monoclonal or polyclonal lymphoproliferative lesions that occur in immunosuppressed 
recipients after solid-organ or bone marrow transplantation. cHL occurs in the post-
transplant setting, most often in renal transplant patients, is almost always EBV-positive and 
should complete the diagnostic criteria for cHL (Adams et al., 2009; Knight et al., 2009; 
Rohr et al., 2008; Swerdlow et al., 2008c). All patients received post-transplant 
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immunosuppression and/or antiviral agents (Dharnidharka et al., 2004; Goyal et al., 1996; 
Krishnamurthy et al., 2010). Clinically, the majority of patients are men and all ages are 
affected. Generally, the time from transplant to the onset of the disease ranges from few 
months (4–6 months) to several years, with a median time of 113 months. Half cases 
presented as extranodal masses, especially in the liver or in the lung even if other extranodal 
sites (especially tonsil) can be involved. The best therapeutic approach is not well defined 
yet. Recently, rituximab has gained favor in the treatment of PTLD because of its targeting 
of CD20-positive B cells, with fairly promising results (Pham et al., 2002). 
The iatrogenic lymphoproliferative disorders are lymphoid proliferations or lymphomas 
that arise in patients treated with immunosuppressive drugs. Among iatrogenic 
lymphoproliferative disorders, other than PTLD, there is an increase in frequency of cHL 
and lymphoid proliferations with Hodgkin-like features. Thus, lesions containing RS-like 
cells but do not fulfill the criteria of CHL, the so-called Hodgkin-like lesions, have been 
included in this setting (Gaulard et al., 2008). Because CHL has only recently been 
recognized as an iatrogenic complication, few cases have been reported in the medical 
literature (Gaulard et al., 2008). 
10. Antineoplastic therapy in HL: From classical to biological therapies  
Chemotherapy and radiotherapy remain the cornerstone of HL treatment. Especially, 
polychemotherapy schedules have increased the survival rates in these patients along the 
last decades. Nevertheless, up to 30% and 10% of patients will recur and die of HL in 
advanced and early disease respectively, and unlike what happened in non Hodgkin 
lymphomas, newer active compounds against HL have not been introduced in clinic since 
the early 1970s. In addition, patients exposed to chemotherapy and radiation fields are at 
highest risk of lethal second malignancies (Friedberg, 2011). Therefore it would be more 
than desirable having new therapeutic drugs and strategies for a better control of the disease 
and minimizing toxicity of therapy, especially when relapses occur. 
10.1 Conventional treatment 
Nowadays HL is considered one of the most oncological curable diseases, as a matter of fact 
of its extremely chemo and radiosensitivity. Among chemotherapy options, ABVD 
(doxorubicin, bleomycin, vinblastine and dacarbazine) represent the standard schedule for 
HL treatment in the majority of centers worldwide. However the management of advanced-
stage cHL is often predicated on the IPS, and thus escalated BEACOPP (bleomycin, 
etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) is 
another schedule to consider, especially in high-risk patients with IPS scores of 4 or greater 
(Diehl et al., 2003). Therefore, an apparently more effective initial treatment may be 
unattractive because of increased toxic effects (Connors, 2011) and highest risk of second 
malignancies, especially in relation with large radiation fields (Ng et al., 2002). 
Canellos et al showed in 1992 that ABVD was equally effective and less toxic than MOPP 
(mechlorethamine, vincristine, procarbazine, prednisone)  or MOPP alternating with ABVD, 
and this has subsequently become the chemotherapy of choice worldwide (Canellos et al., 
1992). Although standard ABVD can cure most of HL, advanced stage- high risk patients 






Diehl, 1998). The HD9 trial conducted by Diehl et al showed that among patients with 
advanced-stage cHL, ABVD is insufficient for patients with an IPS of 4 or more (Diehl A et 
at, 2003). In this trial of the German Hodgkin Study Group (GHSG), 1,195 patients with 
advanced-stage HL were recruited and randomized between COPP-ABVD, standard 
BEACOPP, and escalated BEACOPP. For patients with an IPS of 4 or greater, the more 
intensive regimen improved the freedom from treatment failure from 59% to 82% and OS 
from 67% to 82%. It is important to underscore that there was no significant difference for 
the more favorable groups. A 10-year update of this study confirms superiority of escalated 
BEACOPP over COPP-ABVD for the high-risk patients (Diehl et al., 2003). However, there is 
increased late toxicity with escalated BEACOPP, with more risk of sterility, infections and 
secondary leukaemia’s, and thus universal application of this schedule for advanced-stage 
disease remain difficult to implement.  
In addition of chemotherapy, radiotherapy is another treatment modality frequently used in 
HL. It is generally indicated in early disease, regardless of the favorable/unfavorable 
stratification, and when bulky disease is present, or there remain residual foci of disease 
after chemotherapy in advanced HL. 
10.2 Impact of chemotherapy and radiotherapy on tumoral microenvironment 
In the last few years, many interesting data have emerged about the enormous impact of the 
antineoplastic treatments into the immune microenvironment of the tumors, which 
demonstrate a sort of cancer vaccination effect (Haynes et al., 2008). In this sense, 
chemotherapeutics like anthracyclines (included in all of the upfront standard treatments of 
HL) and radiotherapy seem to induce a type of apoptotic death via calreticulin exposure and 
release of the pro-inflammatory factor High Mobility Group Box-1 (HMGB1) with well 
known immune stimulating properties (Tesniere et al., 2008). 
Anthracyclines can induce a highly potent immune response by increasing antigen 
(neoantigens) threshold and presentation (via antigen presenting cells), with enhancement 
of T-cell response and generation of memory T cells (Obeid et al., 2007a). Other 
chemotherapeutics like cyclophosphamide, etoposide and taxanes have also proved to have 
an immunogenic effect in preclinical models (Tsavaris et al., 2002), however evidence is 
scarce and further investigation is required.  
These new concepts might serve to consider chemotherapeutics like anthracyclines as less 
empirical and more specific drugs, and thus it would be desirable to customize 
chemotherapies taking into account their potential effects on microenvironment. In this 
sense, there is an interesting field of clinical research to discover that may combine classical 
CT agents with immunogenic effects with boosting costimulators molecules like cytokines 
(GM-CSF, IL2) (de la Cruz-Merino et al., 2008). Specifically in the case of the anthracycline´s 
effect on cancer cells, the calreticulin exposure do not induce DC maturation which is, on the 
contrary, one of the main effects of cytokines like GM-CSF that induce selective DC 
maturation and activation, giving a strong rationale to combine these two therapeutic 
modalities (anthracyclines and GM-CSF). These combinatorial strategies may eventually 
sustain immunogenic effect of tumoral cell death. Regarding to this, biomarkers of immune 
activity should be of the greatest interest, in order to serve as proof of principle of efficacy 
with an earlier detection of the eventual benefits of oncological treatments in patients. 
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Furthermore, monitoring changes detected during oncological treatments in blood samples, 
especially in immunophenotype, regulatory T cells amount and TCD8/regulatory T cells 
ratio, may represent interesting biomarkers to analyze and validate in the future. 
As happen with chemotherapy, the intrinsic radiosensitivity of malignant lymphocytes is 
extremely high. Although the underlying mechanisms which explain it are not fully 
elucidated, recently new evidence is emerging about some changes induced by radiation at 
a molecular level, which may provoke a type of cell death highly immunogenic (Formenti & 
Demaria, 2009). Ionising radiation has different immune effects regarding the dose 
administered, and while in the case of low doses the final effect is mostly protumorigenic, at 
higher doses with cytotoxic activity, cell death may induce tumoral neoantigens which can 
be embraced by DC, and thus activate an effective adaptive immune response (Apetoh et al., 
2007). As with anthracyclines, the two critical mediators of this process seem to be 
translocation of calreticulin to the cell surface and release of HMGB1 by the dying cells 
(Formenti & Demaria, 2009). Both of them trigger danger signals which activate immune 
mechanisms. In addition, surviving cancer cells after radiation show increased expression of 
death receptors, adhesion molecules (ICAM-1) and major histocompatibility complex class I 
(MHC-I), which activate APCs (Obeid et al., 2007b). 
To conclude, some groups argue that these immune effects are the major determinants of the 
therapeutical success of the antineoplastic treatments in oncological diseases, including HL. 
10.3 Modern therapeutic approaches targeting the tumor microenvironment 
Apart from chemotherapy and radiotherapy, other biological compounds with significant 
effects upon tumor microenvironment like unconjugated and conjugated monoclonal 
antibodies, radioimmunconjugates, immunotoxins and novel immunomodulatory 
compounds like lenalidomide are under clinical investigation, and at this moment they 
represent the most promising therapeutical strategies in HL. Recently, Kasamon et al 
revised this topic (Kasamon & Ambinder, 2008) and pointed out three major HL therapeutic 
targets: EBV, CD20 and CD30.  
As previously cited, up to 40-60% of cHL might be associated with EBV and thus some EBV 
antigens expressed on HL cells like latent membrane protein 1 and 2 (LMP1 and LMP2) 
have been postulated as eventual immunotherapeutic targets. Some interesting results have 
been obtained with the use of adoptive cellular immunotherapy with EBV-specific CTL 
among patients with EBV-associated posttransplant lymphoproliferative diseases (Haque T 
et al., 2007), rendering a proof of principle of activity for this approach. In a small study of 
16 patients with relapsed or high risk EBV+ lymphoproliferative diseases that included cases 
of HL, infusions of autologous LMP2- specific CTL induced clinical responses with tumor 
regression in 5 of 6 patients with previously detectable tumor (Lucas et al., 2004). 
After elucidation of the B cell origin of H/RS in classical HL, targeting B cell antigens on HL 
has gained renewed interest. Specifically in classical HL, the monoclonal antibody anti-
CD20 Rituximab has shown activity as single agent or combined with chemotherapies like 
ABVD and gemcitabine in different clinical settings (Kasamon & Ambinder, 2008). Impact of 
rituximab on tumor microenviroment by depleting benign CD20+ cells, is postulated as the 
main antineoplastic mechanism of action of this drug in HL, independently of CD20 






lymphocyte predominant Hodgkin lymphoma, with impressive clinical results (Rehwald et 
al., 2003; Ekstrand et al., 2003) that merit further investigation. 
Among new molecular targets in HL, the member of the tumor necrosis factor (TNF)-
receptor family CD30 merits special consideration. CD30 is expressed abundantly on RS 
cells of HL, and in other numerous lymphoid malignancies of B-, T-, and natural killer (NK)-
cell origin (Deutsch et al., 2011). Regarding its biological activity CD30 has pleiotropic 
biologic functions, being capable of promoting cell proliferation and survival as well as 
inducing antiproliferative responses and cell death. Final effects of CD30 activation seem 
largely dependent  on the microenvironment context (Deutsch et al., 2011). Unconjugated 
anti-CD30 antibodies have been tested in phase I and II studies showing limited clinical 
activity (Kasamon & Ambinder, 2008).  On the contrary, another attractive approach as it is 
the use of antibody–drug conjugates (ADCs) have rendered better results.  
Brentuximab vedotin (SGN-35) is an ADC consisting of chimeric anti-CD30 antibody cAC10 
(SGN-30) conjugated to the tubulin destabilizer monomethylauristatin E (MMAE) (Okeley et 
al., 2010). In an initial phase I dose escalation study, brentuximab vedotin was administered 
at a dose of 0.1–3.6 mg/kg every 3 weeks to 45 patients with relapsed or refractory CD30-
positive lymphomas, primarily HL and ALCL (Younes et al., 2010). Brentuximab vedotin 
was well tolerated and associated mainly with grade 1 or 2 adverse events including 
neutropenia and peripheral neuropathy. Objective response was observed in 17 (38%) 
patients, including 11 (24%) complete remissions, with a median duration of response of 9.7 
months. Tumor regression was observed in 86% of patients. The maximum tolerated dose 
was 1.8 mg/kg, and of 12 patients who received this dose, six patients (50%) had an 
objective response (Younes A et al, 2010). A second phase I study, with weekly brentuximab 
vedotin resulted in an objective response rate of 59% and rapid median time to response. 
Anti-tumor activity was similar to that observed for dosing once every 3 weeks. However, 
significant peripheral neuropathy was observed with continued weekly dosing, so the 
administration every 3 weeks was preferred for phase II studies (Deutsch et al., 2011). 
Clearly, brentuximab vedotin is an exciting new agent in the setting of relapsed HL and 
other lymphoid neoplasms CD30+. Multiple clinical trials are ongoing including different 
clinical settings and combinations with chemotherapy, in order to find the safer and more 
successful way of administering this drug. 
11. Body’s own power protection challenges in HL 
Evidences in the literature suggest that targeting elements of the tumor microenvironment, 
or signaling pathways in tumor cells activated as a consequence of stromal interactions, may 
prove a useful therapeutic strategy to prevent tumor development and progression. 
However, given the tumor cells’ ability to circumvent various therapeutic agents when 
given as monotherapy, the success of these agents is likely to be seen when used in 
combination with existing treatments. 
Apart from the infiltrating immune competent cells, the complex tissue network of the 
tumor microenvironment is also formed by neoangiogenesis, stromal cells, and a 
differentiated and specific extracellular matrix. Among stromal cells, there are 
macrophages—derived from hematopoietic stem cells, fibroblasts, adipocytes, and 
osteoblasts.  In order to delay or circumvent tumor progression, a number of strategies are 
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being developed to disrupt tumor-stroma interactions (Hiscox et al., 2011). Macrophages 
and fibroblasts within the tumor microenvironment present an important point for 
therapeutic intervention by using agents which reverse their phenotype or block key growth 
factor receptors (Allavena et al., 2005; Banciu et al., 2008; Hagemann et al., 2008; Hiscox et 
al., 2011; Karin & Greten, 2005). On the other hand, the regulation of adhesion between 
cancer cells and the surrounding matrix by different kind of integrins activates tumor cell 
signaling pathways that result in growth progression, invasion and migration (Green et al., 
2009; Hiscox et al., 2011; Inoki et al., 2002; Kim et al., 2009; Parsons et al., 2008; Stupp & 
Ruegg, 2007).  
The different immunotherapeutic models that have been tested for the treatment of HL 
include unconjugated monoclonal antibodies (Ansell et al., 2007; Bartlett et al., 2008; Klimm 
et al., 2005), immunotoxins (Falini et al., 1992; Kreitman et al., 2000),  
radioimmunoconjugates (Klimm et al., 2005; Schnell et al., 2005) and, most recently, 
immunomodulatory compounds (Bollard et al., 2004; Borchmann et al., 2002; Davies et al., 
2001; Hartmann et al., 2001; Hartmann et al., 1997; Maier & Hammond, 2006; Roskrow et al., 
1998). Some strategies, in particular radioimmunotherapeutic approaches and 
immunotoxins have already shown significant effectivity (Friedberg, 2011). First experiences 
with relatively non-toxic immunomodulatory compounds have implemented a whole new 
kind of immunotherapy in NLPHL where the anti-CD20-antibody Rituximab might be the 
future effective but less toxic treatment (Ekstrand et al., 2003; Schulz et al., 2008). 
The integration of the new biologic markers evaluated in HL, that clearly driving force for 
an abnormal local and systemic antitumor immunity in HL, make of HL an ideal candidate 
for immunotherapeutic strategies (Rathore & Kadin, 2010; Younes, 2009). The pro-survival 
and pro-death receptors expressed by tumoral cells are currently being explored for novel 
treatment strategies by using a variety of naked and conjugated monoclonal antibodies. 
Furthermore, signaling pathways triggered by these receptors and other intracellular 
proteins can now be therapeutically inhibited by a variety of small molecules. Nowadays, 
the present challenge remains to know the best way to implement immunotherapeutic 
concepts into the current treatment concepts of HL in order to conserve or even improve the 
good long term survival in these patients and to reduce toxicity and long-term side-effects. 
12. Conclusion 
Although the relatively good prognosis and high current overall cure rate of cHL, it is 
important to underscore that clinicobiological factors still remain the main information to 
guide treatment policies in HL. Due to the fact that this disease is commonly diagnosed in 
young population, and antineoplastic treatments may induce worrying iatrogenic 
consequences in terms of secondary tumors (solid and hematologic malignancies), 
cardiopathies or respiratory long-term morbidities among others, it is indispensable to 
administer always the minimum effective and curative therapy. In this sense, beyond the 
well known clinical risk factors, interim information in the course of chemotherapy of PET 
scans will probably aid in the next future to apply a less empiric and more tailored and 
personalized treatment. Since early 90´s ABVD schedule represent the standard treatment of 
HL for curative purposes worldwide and little has changed in clinical practice in the last 
two decades. However there is room for improvement since a significant percentage of 






The recent research activities led to a better understanding of the phenotype, molecular 
characteristics, histogenesis, and possible mechanisms of HL lymphomagenesis. There is 
complete consensus on the B-cell derivation of the tumor in most cases, and on the relevance 
of EBV infection and defective cytokinesis in at least a proportion of patients. The influence 
of the cellular components of the microenvironment and that of the elaborate network of 
interactions they produce, on the clinical course of HL, has progressively emerged over the 
past decades. The expression of a variety of cytokines and chemokines by the tumoral cells 
is believed to drive an abnormal immune response and additional factors secreted by 
reactive cells in the microenvironment help to maintain the inflammatory milieu. In these 
conditions, tumoral cells manipulate microenvironment, permitting them to develop their 
malignant phenotype fully and evade host immune response attack. The interplay between 
tumoral cells and the reactive microenvironment determines not only the histological 
morphology and classification but also the clinicopathological features and prognosis of 
these patients. Genes and proteins expression signatures derived from immune cells have 
demonstrated to correlate well with response to treatments the outcome of HL patients 
respectively. This could be critical to the development of adoptive T-cell therapies that 
target the virus or different cell components of HL microenvironment. In aggressive HL, the 
development of prognostic systems modelled on the integration of biologic prognostic 
markers appears essential for more appropriate risk stratification.  
New knowledge about impact of chemotherapy upon microenvironment has changed old 
paradigms, conferring to some cytotoxic agents like anthracyclines immunogenic properties 
that can explain the final mechanism of action of these drugs. These discoveries are 
extremely important since give a strong rationale to exploit this activity in the context of 
combinatorial strategies that might include other immunogenic agents like cytokines and 
monoclonal antibodies, among others. Therefore, it is conceivable to hypothesize that 
chemotherapy can still improve its efficacy in HL in the next future. Furthermore, recently 
new molecules have shown impressive clinical activity in HL. It is the case of the antibody-
drug conjugate anti-CD30 brentuximab vedotin that have obtained very promising results in 
relapsed CD30+ lymphomas, and thus has given place to ongoing phase III confirmatory 
studies.  
To summarize, the incorporation of PET scans in HL diagnostic and follow-up algorithms, 
the widespread use of the new prognostic molecular and biological factors at diagnosis, the 
new highly effective molecules and the recent knowledge regarding chemotherapy effects 
on microenviroment, permit forsee a different and customized therapeutical approach to HL 
in the next future. 
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